EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu und 6 weitere

Advanced Science · 2026-02 · 13 (10)

DOI: 10.1002/advs.202517792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 23.12.2025. Verfasst von Shiji Fang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Nanomedicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lishui Innovation Consortium-Key R&D Program Projects, National Traditional Chinese Medicine Comprehensive Reform Demonstration Zone Science and Technology Co-construction Project, Fund of the Zhejiang Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor senescence, a double‐edged sword, can suppress tumor growth but also promote immune evasion if not properly cleared. Herein, a cell membrane‐coated ZIF‐8@MnOx nanoplatform co‐loaded with doxorubicin (DOX) and piperlongumine (PL), termed mPDZM, is developed to remodel the senescence‐mediated immune response in hepatocellular carcinoma. PL synergizes with DOX to amplify intracellular oxidative stress, which promotes both the killing of tumor cells and the clearance of senescent cells. The biomimetic ZIF‐8@MnOx nanoplatform potentiates the efficacy of DOX and PL by integrating targeted delivery, hypoxia relief, and redox homeostasis disruption. mPDZM remodels the immunosuppressive microenvironment by regulating SASP release, inducing immunogenic cell death, and activating the STING signaling pathway. In vivo, mPDZM exhibits preferential tumor accumulation and minimal systemic toxicity. mPDZM treatment leads to significant tumor suppression both in the senescent and non‐senescent tumor models. Moreover, mPDZM effectively promotes CD8 + T cell and NK cell infiltration, while reducing immunosuppressive Treg cells and M2‐like macrophages. In combination with anti‐PD‐L1 therapy, mPDZM further potentiates antitumor immunity and induces a robust abscopal effect against distant tumors. Collectively, these findings unveil a new paradigm that integrates senescence modulation with immune activation via a biomimetic nanotherapeutic platform and offers a promising combinatorial approach to overcome immune resistance in solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsImmunotherapyNanomedicineBiomimeticsAnimalsMiceHumansDoxorubicinCellular SenescenceBiomimetic MaterialsTumor MicroenvironmentCell Line, TumorPiperidones

Stichwörter der Autor:innen

anticancer immunotherapycombination therapyhepatocellular carcinomananoparticlesradiofrequency ablation

Substanzen

DoxorubicinpiperlonguminePiperidones

Autor:innen und Institutionen

  • Zhejiang Key Laboratory of Imaging and Interventional Medicine, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
  • Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, 215123, China.
  • Cancer center, Lishui Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
  • Department of Radiology, Lishui Central Hospital, the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, 323000, China.
  • School of Pharmacy, Jiamusi University, Jiamusi, 154007, China.

ORCID-Profile: Jiansong Ji

Förderung

  • Lishui Innovation Consortium-Key R&D Program Projects
  • National Traditional Chinese Medicine Comprehensive Reform Demonstration Zone Science and Technology Co-construction Project
  • Fund of the Zhejiang Provincial Natural Science Foundation
  • Zhejiang Medicine and Health science and Technology Project
  • Zhejiang Province Traditional Chinese Medicine Inheritance and Innovation Talent Program
  • Lishui Key R&D Program Projects
  • National Natural Science Foundation of China

Zitieren

APA

Fang, S., Zheng, L., Lin, B., Chen, J., Hou, D., Ding, Y., Han, M., Qin, P., Wang, M., Guo, X., Zhang, Y., Shu, G., Wu, F., Tu, J., Chen, M., Zhao, Z., Liu, Z., & Ji, J. (2026). Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science, 13(10). https://doi.org/10.1002/advs.202517792

Vancouver

Fang S, Zheng L, Lin B, Chen J, Hou D, Ding Y, et al. Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma. Advanced Science. 2026;13(10). doi:10.1002/advs.202517792

BibTeX
@article{Fang2026,
  author = {Fang, Shiji and Zheng, Liyun and Lin, Bin and Chen, Jiale and Hou, Dehai and Ding, Yiming and Han, Mengzhu and Qin, Pan and Wang, Mengyuan and Guo, Xiaoju and Zhang, Yeyu and Shu, Gaofeng and Wu, Fazong and Tu, Jianfei and Chen, Minjiang and Zhao, Zhongwei and Liu, Zhuang and Ji, Jiansong},
  title = {Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {10},
  doi = {10.1002/advs.202517792}
}
Kostenlos starten →